Cuenca, Dalia and Aguilar-Soto, Mercedes and Mercado, Moisés (2022) A Case of Graves’ Disease Following Vaccination with the Oxford-AstraZeneca SARS-CoV-2 Vaccine: Case Report and Review of the Literature. European Journal of Case Reports in Internal Medicine, 9 (4). pp. 1-5. ISSN 2284-2594
|
Text
3275-Article Text-28348-1-10-20220413.pdf - Published Version Download (226kB) | Preview |
Abstract
A 57-year-old man presented to the outpatient clinic with tremor, palpitations, weight loss and fatigue 1 week after receiving the first dose of the Oxford-AstraZeneca SARS-CoV-2 vaccine (ChAdOx1 nCoV-19). Laboratory studies showed a suppressed TSH with elevated total and free T4. Thyroid peroxidase and thyroglobulin antibodies were elevated but thyrotropin receptor autoantibodies were indeterminate. Thyroid scintigraphy with technetium Tc-99m pertechnetate revealed increased diffuse, symmetric uptake. The patient was treated with thiamazole 15 mg three times a day and propranolol with resolution of his symptoms and normalization of his thyroid function tests until discontinuation of the antithyroid drug 6 months after symptom onset.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Graves' disease, AstraZeneca, COVID-19 |
| Subjects: | 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) |
| Depositing User: | Marina Spanti |
| Date Deposited: | 06 May 2022 09:39 |
| Last Modified: | 06 May 2022 09:39 |
| URI: | http://eprints.bice.rm.cnr.it/id/eprint/21860 |
Actions (login required)
 |
View Item |
